3 terminated, 1 completed, 1 withdrawn. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 3, Completed 1, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow Adaptimmune: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) Autologous genetically modified ADP-A2M4CD8 cells - Esophageal Cancer, Esophagogastric Junction Cancer | Phase 2 | Terminated | Adaptimmune | 3 | 2021-09-15 | 2024-09-04 |
| SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer ADP-A2M4 in combination with pembrolizumab. - Head and Neck Cancer | Phase 2 | Withdrawn | Adaptimmune | 2020-07-02 | 2021-11-16 | |
| CT Antigen TCR-Engineered T Cells for Myeloma Treatment with NY-ESO-1c259-modified T cells - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Adaptimmune | 6 | 2013-10-15 | 2019-01-10 |
| CT Antigen TCR-redirected T Cells for Ovarian Cancer. NYESO-1c259 T cells - Ovarian Cancer | Phase 1 / Phase 2 | Completed | Adaptimmune | 9 | 2013-07-09 | 2019-06-27 |
| Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T - Melanoma | Phase 1 / Phase 2 | Terminated | Adaptimmune | 4 | 2011-06-01 | 2019-01-10 |
Neoplasm Metastasis (3) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1)
Therapeutics (1) · pembrolizumab (1)
United States (5) · Canada (1) · Spain (1)
Edward Stadtmauer, MD (1) · Gerald P Linette, MD, PhD (1) · Harriet Kluger, MD (1) · Kunle Odunsi, MD, PhD (1)